AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -…

ALAMEDA, Calif. & LONDON, Ontario--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeXs UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A. The goal is to eliminate the need for immunosuppressive medications following Cell Pouch cell transplantation.

The research collaboration will evaluate whether Sernovas pluripotent stem cell-derived pancreatic islet beta cells engineered with AgeXs UniverCyte technology can evade human immune detection. The complementary combination of technologies could enable the transplantation of therapeutic cells in patients with type I diabetes in an off-the-shelf manner using Sernovas Cell Pouch, without human leukocyte antigen (HLA) tissue matching or concurrent administration of immunosuppressive medications. With a similar intent, pluripotent stem cell-derived or adult donor-derived human Factor VIII-releasing cells modified with AgeXs UniverCyte will be evaluated in Sernovas hemophilia A program.

Under the terms of the agreement, Sernova has been granted a time-limited, non-exclusive research license by AgeX. A commercial license for Sernova to utilize UniverCyte to engineer cellular products for therapeutic and commercial purposes may be negotiated between the companies pending successful study outcomes.

The UniverCyte technology aims to mask therapeutic cells derived from pluripotent stem cells or adult donors from human immune detection to allow for off-the-shelf cellular products without the need for immunosuppressant medications which may have potent side effects, or HLA-matching between donor and patient. UniverCyte uses a novel, modified form of HLA-G, a potent immunomodulatory molecule, which in nature protects an unborn child from their mothers immune system. In almost all human cells, native HLA-G expression is silenced after birth. AgeXs modified HLA-G shows evidence of being resistant to this silencing, thereby potentially allowing for long-term, stable and high expression of the immunomodulatory effect.

Sernova plans to utilize the universal therapeutic cells generated through this research collaboration with its Cell Pouch System, a proprietary, scalable, implantable macro-encapsulation device, which, upon implantation, incorporates with tissue and forms highly vascularized chambers. These chambers become a natural environment in the body to house and favor long-term survival and function of therapeutic cells. The Cell Pouch System has shown initial safety and efficacy indicators in an ongoing Phase I/II clinical study at the University of Chicago and in a preclinical model of hemophilia A when assessed with human cells corrected to produce Factor VIII.

We are thrilled with our collaboration with Sernova, which is at the forefront of cellular therapies for diabetes and hemophilia and is already in the clinic for the former. The combination of AgeXs UniverCyte to cloak cells from a patients immune system and Sernovas Cell Pouch technologies to permit cells to function long-term upon transplantation would be a landmark for regenerative medicine. This deal marks another important step in AgeXs collaboration and licensing strategy to work with the very best people, companies and institutions in the world of regenerative medicine, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We look forward to working with AgeX and its outstanding team as we continue to identify and evaluate technologies complementary to Sernovas therapeutic platform and expand our immune protection offerings. AgeXs UniverCyte technology is a significant advancement in the field of cell therapy and a perfect fit with Sernovas Cell Pouch technologies and therapeutic pipeline with its potential benefit over current immunosuppressive strategies for regenerative medicine therapeutics, said Dr. Philip Toleikis, President and CEO of Sernova Corp.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About Sernova Corp.

Sernova Corp is developing regenerative medicine therapeutic technologies using the Cell Pouch System, a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, there can be no assurance that Sernovas planned use of AgeXs UniverCyteTM gene technology will successfully generate immune-protected universal therapeutic cells for use in combination with Sernovas Cell PouchTM for the treatment of type I diabetes and hemophilia A or any other disease, and there can be no assurance that AgeX and Sernova will enter into a commercial license for the use of UniverCyteTM in a therapeutic or other product. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Forward-Looking Statements for Sernova

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential and similar expressions, or that events or conditions will, would, may, could or should occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements including those related to the potential of Univercyte combined with Sernovas technologies are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernovas management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

See the original post here:
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -...

In Vitro Toxicology Testing Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario – Cole of Duty

[112 Report Pages] This market research report identifies Laboratory Corporation of America Holdings, Charles River Laboratories, Inc, Thermo Fisher Scientific, Eurofins Scientific, Agilent Technologies, Inc., as the major vendors operating in the global in vitro toxicology testing market. This report also provides a detailed analysis of the market by toxicology end points (systemic toxicity, cytotoxicity testing, genotoxicity testing, ocular toxicity, organ toxicity, dermal toxicity, neurotoxicity, and others), industry type (pharmaceutical and biopharmaceutical, cosmetics, chemical, diagnostics, and food industry), and region (North America, Europe, Asia Pacific, and Rest of the World).

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/9863

Infoholicsmarket research report predicts that the globalin vitro toxicology testingmarket will grow at a CAGR of8.2%during the forecast period 20182024.The market for in vitro toxicology testing is driven by high opposition to animal testing, increased cost related to animal-based toxicity testing, and increasing R&D expenditure for early stage toxicity testing. Whereas, the lack of in vitro models and decreased adoption rate are limiting the growth of the in vitro toxicology testingmarket to an extent.

According to the in vitro toxicology testingmarket analysis, Europe accounted for the largest share of the global in vitro toxicology testingmarket followed by North America in 2017. The reason is the upsurge in the investments by the European Commission in R&D to develop substitute methods to in vitro testing is driving the demand in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period due to increasing number of contract research organizations offering testing services, advancements in healthcare infrastructure, increasing investments in the biopharmaceutical sector, and upward economic conditions in the region.

Competitive Analysis and Key Vendors:

There is an increase in collaborations between companies on in vitro testing of compounds. For instance, in December 2016, Evotec and Celgene entered into a drug discovery collaboration for neurodegenerative diseases. According to agreement terms, Celgene will use Evotecs unique induced pluripotent stem cell (iPSC) platform that enables systematic drug screening in patient-derived disease models. In June 2017, Censo Biotechnologies Ltd. collaborated with Evotec AG to source and provide patient-derived induced pluripotent stem cells to support Evotecs drug discovery iPSC platform. In addition, the companies are also coming up with new products for in vitro testing. For instance, in January 2018, STEMCELL Technologies Inc. released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the laboratory.

Some of the In Vitro Toxicology Testing Market key vendorsare:

Other prominent vendors in the global in vitro toxicology testing market are Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories, Gentronix Limited, Promega Corporation, MB Research Laboratories, Evotec AG (Cyprotex plc), Catalent, Inc., Qiagen N.V., and niche players.

In Vitro Toxicology Testing Market by Toxicology End Points:

In 2017, the systemic toxicity accounted for the highest market share due to the availability of a wide range of sub-studies, which ensure total analysis of toxicity and safety margin of the testing compounds.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/9863

In Vitro Toxicology Testing Market by Industry type:

In 2017, the pharmaceutical and biopharmaceutical industry occupied significant market share and the cosmetics industry is expected to hold a high percentage during the forecast period. Increased support of regulatory authorities to use in vitro and in silico methods instead of animal testing to check toxicology is driving the growth of the cosmetic industry.

In Vitro Toxicology Testing Market Benefits:

The report provides detailed information about the services offered by in vitro toxicology testingin various therapeutic verticals and regions. With that, key stakeholders can find out the major trends, drivers, investments, and vertical players initiatives. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Additionally, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the in vitro toxicology testingmarket.

Continued here:
In Vitro Toxicology Testing Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario - Cole of Duty

Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation – SMA News Today

Heart problems associated with spinal muscular atrophy(SMA) may be caused partially by calcium dysregulation in heart muscle cells in the absence of the survival motor neuron(SMN) protein, a study suggests.

These findings shed light not only on the underlying mechanisms of heart problems in SMA which may open new therapeutic avenues but also support the monitoring of heart function in this patient population.

The study, SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs, was published in the journal Skeletal Muscle.

SMA is caused by the loss of SMN, a protein produced in several cell types throughout the body and involved inmultiple and fundamental cellular processes. While SMN deficiency in motor nerve cells is considered the diseases root cause, increasing evidence suggests that other cells and organs in the body also are particularly affected, including the heart.

Cardiovascular problems have been reported in patients with the most severe severeforms of SMA and in mouse models of the disease. Moreover, a previous study supported by theSMA Foundation showed that SMA patients have higher-than-normal levels of several heart failure markers, suggesting that sufficient levels of SMN are essential for normal heart function.

However, the mechanisms behind these SMA-associated heart problems remain largely unknown and no study has established that SMN deficiency directly affects heart function.

Researchers have now evaluated whether SMN deficiency compromised the contractile function of heart cells isolated from a mouse model of a severe form of SMA and also those generated from SMA patients-derived induced pluripotent stem cells (iPSCs).

iPSCs are fully matured cells that researchers can reprogram in a lab dish to revert them back to a stem cell state that has the capacity to differentiate into almost any type of cell.

Results showed that the levels of three heart failure markers atrial natriuretic peptide, brain natriuretic peptide, and skeletal alpa-actin were significantly increased in heart tissue from SMA mice prior to considerable neuromuscular degeneration, compared with that from healthy mice.

This suggested that mechanical function of the heart may be altered early in the disease progression of this severe SMA mouse model, the researchers wrote.

In agreement, heart cells from SMA mice showed impaired contractile function, compared with cells from healthy mice. The team noted that contraction problems in the heart often are associated with calcium dysregulation and lower levels of SERCA2, an enzyme that controls calcium levels inside cells.

Further analysis showed that SMN-deficient heart cells, from both SMA mice and SMA patients, had a significant drop in SERCA2 levels and impaired calcium dynamics, compared with healthy cells.

Notably, these deficits were at least partially corrected when patient-derived cells were modified to increase their production of SMN protein. Conversely, heart cells derived from healthy individuals and forced to lower their SMN production mimicked the deficits seen in SMN-deficient heart cells.

These results demonstrate that SMN regulates SERCA2 [levels] and intracellular [calcium dynamics] in [heart cells] that may impair cardiac function and lead to elevation of heart failure markers, as observed in mice and patients with SMA, the researchers wrote.

The data also suggest that heart cell dysfunction occurs early in the disease course and therefore is likely to be a direct result of SMN loss and not secondary to neurodegeneration, the team noted.

Since deficits in calcium dynamics also were previously reported to occur in SMN-deficient motor nerve cells, the researchers hypothesized that calcium dysregulation may be a common disease mechanism in SMA.

Finally, while neuromuscular degeneration remains the hallmark feature of the disease, impaired heart function may be a contributing factor in disease progression that will require monitoring in light of new therapies that are improving motor function and extending survival, the researchers wrote.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

Total Posts: 85

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Read the rest here:
Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation - SMA News Today

Stem Cell and Regenerative Medicine Market is Expected to Garner USD 14745.7 Million by The End of 2024 By Recording a CAGR of 4.8% (Impact Analysis…

The global demand for stem cell and regenerative medicine is increasing due to the increase in the old age population globally. Further, growing awareness towards stem cell and regenerative medicine is a key growth driver for global stem cell and regenerative medicine market over the forecast period. The global stem cell and regenerative medicine market reached USD 10,200 Million in 2016 by registering a CAGR of 4.8% across the globe. Moreover, the market is expected to garner USD 14745.7 Million by the end of 2024.

The CAGR value Could change due to COVID-19 Pandemic on Global Industry

Request To Fill The form for Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10000055

North America is slated to account for a leading share of 39.7% by 2024 in the stem cell and regenerative medicine market. The growth in the region can be attributed to the presence of a well-established healthcare industry along with expanded funding from the governments organizations. Besides, in 2015, U.S. health care spending increased 5.8% to reach USD 3.2 trillion which is also expected to impel the growth of stem cell and regenerative medicine market in North America. The U.S. is the prominent market driving growth in the region.

Major Key Players of Global Market:

STEMCELL Technologies Inc., AMAG Pharmaceuticals Inc., Osiris Therapeutics, Inc., are some of the prominent players of stem cell and regenerative medicine market.

Additionally, the U.S. stem cell and regenerative medicine market reached USD 3442 Million in 2016 and is expected to reach USD 5056.4 Million by the end of 2024, expanding at a CAGR of 4.9% over the forecast period i.e. 2017-2024. U.S. stem cell and regenerative medicine market are expected to achieve a Y-o-Y growth rate of 5.6% in 2024 as compared to the previous year.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request To Fill The form for Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10000055

Europe market is expected to expand at a significant CAGR of 4.9% during the forecast period i.e. 2017-2024. Growth and expansion of the pharmaceuticalindustry in the region are expected to be the key factor behind the growth of stem cell and regenerative medicine market in the European region. Further, increasing the application of stem cell and regenerative medicine is expected to fuel the growth of Europe stem Cell and regenerative medicine market during the forecast period. France & Germany are the major contributors to the growth of the stem cell and regenerative medicine market.

Globalstem cell and regenerative medicinemarket are segmented on the basis of product into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and very small embryonic-like stem cells. Among these segments, the adult stem cells segment (82.9% share in 2016) occupies the largest market of stem cell and regenerative medicine across the globe.

Further, the global adult stem cells market is anticipated to reach USD 12,290.1 Million by the end of 2024 from USD 8,456.6 Million in 2016. Moreover, this segment is anticipated to flourish at a CAGR of 4.9% over the forecast period. In addition, wide-scale application of adult stem cells in the cell regeneration of various diseases is expected to supplement the growth of the global adult stem cells market.

Request To Fill The form for Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10000055

In the end-user segment, the pharmaceutical industry segment is estimated to remain highest during the forecast period. This segment contributed around 82.9% market share of total stem cell and regenerative medicine market in 2016. Further, this segment is projected to capture 83.1% market share by 2024. Further, the pharmaceutical industry segment is projected to achieve a Y-o-Y growth rate of 5.5% in 2024 as compared to the previous year.

Table of Content:

Dont miss the business opportunity of the Global Market. Consult our analyst and gain crucial insights and facilitate your business growth.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations, and organizations with the aim of helping them to take prominent decisions. Our research library comprises more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both the macro level as well as micro-level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis of various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keeps a track of the international and domestic market for any economic changes impacting the products demand, growth, and opportunities for new and existing players.

New Research Reports Available @Kenneth Research:

Stem Cell and Regenerative Medicine MarketOphthalmic Diagnostic Equipment MarketU.S. Ambulatory Surgical Centers MarketNorth America Diabetic Shoes (Footwear) MarketCardiovascular Needle Market3D Hip and Knee implants Market

More:
Stem Cell and Regenerative Medicine Market is Expected to Garner USD 14745.7 Million by The End of 2024 By Recording a CAGR of 4.8% (Impact Analysis...

Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020

Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.

Therapeutic applications of iPSCs are also emerging. In 2013, RIKEN launched the worlds first study of an iPSC-derived cell therapy product, treating the first patient in 2014 with iPS cell-derived retinal sheets.Numerous studies with iPSCs have also been undertaken in Japan, with iPSC-derived treatments being used for the treatment of Parkinsons disease, heart disease, spinal cord injury, and platelet production.

In a world-first achieved in 2016, Cynata Therapeutics received approval to launch the worlds first formal trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product candidate.

While the therapeutic progress is exciting, other methods of commercializing iPS cells have also expanded exponentially.

Since the discovery of iPSC technology nearly 15 years ago, exponential progress has been made in stem cell biology and regenerative medicine.

New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated.

What do you think the next 15 years will hold? Let us know in the comments below.

Read more here:
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020

Induced Pluripotent Stem Cells (iPSCs) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Cole of Duty

Reprocell

Moreover, the Induced Pluripotent Stem Cells (iPSCs) report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Induced Pluripotent Stem Cells (iPSCs) market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Induced Pluripotent Stem Cells (iPSCs) market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=222200&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Induced Pluripotent Stem Cells (iPSCs) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Induced Pluripotent Stem Cells (iPSCs) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Induced Pluripotent Stem Cells (iPSCs) Market, By Deployment Model

5.1 Overview

6 Induced Pluripotent Stem Cells (iPSCs) Market, By Solution

6.1 Overview

7 Induced Pluripotent Stem Cells (iPSCs) Market, By Vertical

7.1 Overview

8 Induced Pluripotent Stem Cells (iPSCs) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Induced Pluripotent Stem Cells (iPSCs) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=222200&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Induced Pluripotent Stem Cells (iPSCs) Market Size, Induced Pluripotent Stem Cells (iPSCs) Market Trends, Induced Pluripotent Stem Cells (iPSCs) Market Growth, Induced Pluripotent Stem Cells (iPSCs) Market Forecast, Induced Pluripotent Stem Cells (iPSCs) Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Electric Vehicle Communication Controller Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Electric Wheelchair Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more from the original source:
Induced Pluripotent Stem Cells (iPSCs) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Induced Pluripotent Stem Cells Market 2020: Growing Tends …

The MarketWatch News Department was not involved in the creation of this content.

May 15, 2020 (The Expresswire) --"Final Report will add the analysis of the impact of COVID-19 on this industry."

The Induced Pluripotent Stem Cells Market report is aimed to deliver an in-depth assessment and assists clients in developing a competitive advantage. The Induced Pluripotent Stem Cells market report covers major players, analyses their strategies, product offerings, and market share. Key insights, market growth rate, are provided along with present and future market scenarios through Induced Pluripotent Stem Cells market size estimates and forecasts over the coming years. The report also analyzes the Induced Pluripotent Stem Cells market growth by categorizing them based on verticals and horizontals and by region.

Induced Pluripotent Stem Cells market trends report offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections.

Request a Sample Copy to Understand the Impact of COVID-19 on Induced Pluripotent Stem Cells Market

Scope of Induced Pluripotent Stem Cells Market:

Key Players Covered in the Global Induced Pluripotent Stem Cells Market Are:

Get a Sample Copy of the Report at -https://www.industryresearch.co/enquiry/request-sample/15362017

On the basis of Types, the Induced Pluripotent Stem Cells Market from 2015 to 2026 is primarily split into:

On the basis of Applications, the Induced Pluripotent Stem Cells Market from 2015 to 2026 is primarily split into:

Key Questions Answered in the Induced Pluripotent Stem Cells Market Report:

Inquire or Share Your Questions If Any Before the Purchasing This Report -https://www.industryresearch.co/enquiry/pre-order-enquiry/15362017

Geographically, the detailed analysis of consumption, revenue, market share, and growth rate, historic and forecast (2015-2026) of the following regions are:

Key Benefits of Induced Pluripotent Stem Cells Market Report:

Purchase this Report (Price 3400 USD for a Single-User License) -https://www.industryresearch.co/purchase/15362017

Detailed TOC of Induced Pluripotent Stem Cells Market Forecast Report 2020-2026:

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Regulatory Scenario by Region/Country

1.4 Market Investment Scenario Strategic

1.5 Market Analysis by Type

1.5.1 Global Induced Pluripotent Stem Cells Market Share by Type (2020-2026)

1.6 Market by Application

1.6.1 Global Induced Pluripotent Stem Cells Market Share by Application (2020-2026)

2 Global Market Growth Trends

2.1 Industry Trends

2.1.1 SWOT Analysis

2.1.2 Porters Five Forces Analysis

2.2 Potential Market and Growth Potential Analysis

2.3 Industry News and Policies by Regions

2.3.1 Industry News

2.3.2 Industry Policies

3 Value Chain of Induced Pluripotent Stem Cells Market

3.1 Value Chain Status

3.2 Induced Pluripotent Stem Cells Manufacturing Cost Structure Analysis

3.2.1 Production Process Analysis

3.2.2 Manufacturing Cost Structure of Induced Pluripotent Stem Cells

3.2.3 Labor Cost of Induced Pluripotent Stem Cells

3.3 Sales and Marketing Model Analysis

3.4 Downstream Major Customer Analysis (by Region)

4 Players Profiles

4.1 Company 1

4.1.1 Company 1 Basic Information

4.1.2 Induced Pluripotent Stem Cells Product Profiles, Application and Specification

4.1.3 Company 1 Induced Pluripotent Stem Cells Market Performance (2015-2020)

4.1.4 Company 1 Business Overview

4.2 Company 2

4.2.1 Company 2 Basic Information

4.2.2 Induced Pluripotent Stem Cells Product Profiles, Application and Specification

4.2.3 Company 2 Induced Pluripotent Stem Cells Market Performance (2015-2020)

4.2.4 Company 2 Business Overview

5 Global Induced Pluripotent Stem Cells Market Analysis by Regions

5.1 Global Induced Pluripotent Stem Cells Sales, Revenue and Market Share by Regions

5.1.1 Global Induced Pluripotent Stem Cells Sales by Regions (2015-2020)

5.1.2 Global Induced Pluripotent Stem Cells Revenue by Regions (2015-2020)

5.2 North America Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

5.3 Europe Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

5.4 Asia-Pacific Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

5.5 Middle East and Africa Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

5.6 South America Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

6 North America Induced Pluripotent Stem Cells Market Analysis by Countries

7 Europe Induced Pluripotent Stem Cells Market Analysis by Countries

8 Asia-Pacific Induced Pluripotent Stem Cells Market Analysis by Countries

9 Middle East and Africa Induced Pluripotent Stem Cells Market Analysis by Countries

9.1 Middle East and Africa Induced Pluripotent Stem Cells Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Induced Pluripotent Stem Cells Sales by Countries (2015-2020)

9.1.2 Middle East and Africa Induced Pluripotent Stem Cells Revenue by Countries (2015-2020)

9.2 Saudi Arabia Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

9.3 UAE Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

9.4 Egypt Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

9.5 Nigeria Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

9.6 South Africa Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

10 South America Induced Pluripotent Stem Cells Market Analysis by Countries

10.1 South America Induced Pluripotent Stem Cells Sales, Revenue and Market Share by Countries

10.1.1 South America Induced Pluripotent Stem Cells Sales by Countries (2015-2020)

10.1.2 South America Induced Pluripotent Stem Cells Revenue by Countries (2015-2020)

10.2 Brazil Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

10.3 Argentina Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

10.4 Columbia Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

10.5 Chile Induced Pluripotent Stem Cells Sales and Growth Rate (2015-2020)

11 Global Induced Pluripotent Stem Cells Market Segment by Types

11.1 Global Induced Pluripotent Stem Cells Sales, Revenue and Market Share by Types (2015-2020)

11.1.1 Global Induced Pluripotent Stem Cells Sales and Market Share by Types (2015-2020)

11.1.2 Global Induced Pluripotent Stem Cells Revenue and Market Share by Types (2015-2020)

11.2 DandO Insurance Sales and Price (2015-2020)

11.3 EandO Insurance Sales and Price (2015-2020)

12 Global Induced Pluripotent Stem Cells Market Segment by Applications

12.1 Global Induced Pluripotent Stem Cells Sales, Revenue and Market Share by Applications (2015-2020)

12.1.1 Global Induced Pluripotent Stem Cells Sales and Market Share by Applications (2015-2020)

12.1.2 Global Induced Pluripotent Stem Cells Revenue and Market Share by Applications (2015-2020)

12.2 Medical institutions Sales, Revenue and Growth Rate (2015-2020)

12.3 Personal Sales, Revenue and Growth Rate (2015-2020)

13 Induced Pluripotent Stem Cells Market Forecast by Regions (2020-2026)

13.1 Global Induced Pluripotent Stem Cells Sales, Revenue and Growth Rate (2020-2026)

13.2 Induced Pluripotent Stem Cells Market Forecast by Regions (2020-2026)

13.3 Induced Pluripotent Stem Cells Market Forecast by Types (2020-2026)

13.4 Induced Pluripotent Stem Cells Market Forecast by Applications (2020-2026)

For Detailed TOC -https://www.industryresearch.co/TOC/15362017#TOC

Contact Us:

View original post here:
Induced Pluripotent Stem Cells Market 2020: Growing Tends ...

Induced Pluripotent Stem Cells Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 – Cole of Duty

Reprocell

Moreover, the Induced Pluripotent Stem Cells report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Induced Pluripotent Stem Cells market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Induced Pluripotent Stem Cells market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=219183&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Induced Pluripotent Stem Cells Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Induced Pluripotent Stem Cells Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Induced Pluripotent Stem Cells Market, By Deployment Model

5.1 Overview

6 Induced Pluripotent Stem Cells Market, By Solution

6.1 Overview

7 Induced Pluripotent Stem Cells Market, By Vertical

7.1 Overview

8 Induced Pluripotent Stem Cells Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Induced Pluripotent Stem Cells Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=219183&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Induced Pluripotent Stem Cells Market Size, Induced Pluripotent Stem Cells Market Trends, Induced Pluripotent Stem Cells Market Growth, Induced Pluripotent Stem Cells Market Forecast, Induced Pluripotent Stem Cells Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Allulose Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Breast Lesion Localization Methods Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the rest here:
Induced Pluripotent Stem Cells Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual…

- Induced pluripotent stem cell (iPSC)-derived MSCs demonstrate higher-level secretion of anti-inflammatory proteins and greater expansion potential than conventional, donor-derived MSCs

- Data include comparative therapeutic benefit in an experimental autoimmune encephalomyelitis (EAE) mouse model

CRANFORD, N.J., May 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that data on NoveCite MSCs will be presented this week at the American Society of Gene and Cell therapy (ASGCT) annual meeting. NC-MSCs are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. Earlier this year, Citius signed an exclusive option agreement to in-license NC-MSCs for acute respiratory distress syndrome (ARDS), including in COVID-19 patients, from Novellus.

The data to be presented show that NC-MSCs secrete higher levels of anti-inflammatory proteins compared to MSCs derived from bone marrow. From the abstract: "Comparative secretome analysis showed overexpression of multiple neuroprotective and anti-inflammatory factors, including CXCL1, VEGF-A, and CXCL5." In addition, NC-MSCs showed therapeutic benefit in an experimental autoimmune encephalomyelitis (EAE) mouse model, delaying disease progression and improving the clinical score compared to the control group, while bone marrow-derived MSCs showed no difference from the control.

"We are pleased to present these data at the annual meeting of the ASGCT," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus. "While conventional MSCs have shown promise in the treatment of inflammatory lung disease, protein secretion and manufacturability remain challenges for these approaches. The data that will be presented this week show that iPSC-derived MSCs secrete higher levels of anti-inflammatory proteins, and exhibit greater expansion potential than bone marrow-derived MSCs. We believe that these properties make iPSC-derived MSCs especially well-suited for an allogeneic cell therapy for ARDS."

"Last month Citius signed an exclusive option agreement with Novellus for worldwide development and commercial rights related to the use of these uniquely derived MSCs for the treatment of ARDS. The pre-clinical data that is being presented at the ASGCT annual meeting adds to our confidence in the higher potency of these MSCs, which we expect will result in better outcomes for patients with COVID-19 and ARDS," stated Myron Holubiak, CEO of Citius Pharmaceuticals. "We intend to study these cells in the clinic later this year to determine safety, efficacy, and the optimal dose of these cells in moderate to severe ARDS patients with COVID-19."

Citius has submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) for use of these MSCs for patients with Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 disease.

Presentation Information:Title:Mesenchymal Stem Cells (MSCs) Generated Using mRNA Reprogramming Show Enhanced Growth Potential, Secretome, and Therapeutic Efficacy in a Demyelinating Disease ModelPresenter:Harris, Jasmine, Novellus, Inc.Date and Time: Wednesday, May 13 | 5:30 PM - 6:30 PM

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Story continues

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 will benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Inc.Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement with Novellus within the option period; our need for substantial additional funds; the ability to access the FDA's CTAP program for the MARCO trial; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks associated with conducting trials for our product candidates, including those expected to be required for any treatment for ARDS and our Phase III trial for Mino-Lok; risks relating to the results of research and development activities; risks associated with developing our product candidates, including any licensed from Novellus, including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; uncertainties relating to preclinical and clinical testing; the early stage of products under development; risks related to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-announces-data-on-novecite-mesenchymal-stem-cells-nc-mscs-to-be-presented-at-the-american-society-of-gene-and-cell-therapy-asgct-annual-meeting-301058260.html

SOURCE Citius Pharmaceuticals, Inc.

See the original post here:
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual...

Novel CAR NK-cell technology could lead to new treatments for lupus, other incurable diseases – Stockhouse

CINCINNATI, May 12, 2020 The explosion in cellular immunotherapy that has revolutionized cancer care in recent years may soon begin showing potential application in treatment for lupus and other autoimmune diseases, thanks to a laboratory breakthrough led by experts at Cincinnati Children's and published in the journal Cell Reports Medicine.

In cancer, CAR T-cell therapy involves engineering T cells with chimeric antigen receptors (CAR) that allow them to recognize specific molecules on the surface of tumor cells. For certain forms of leukemia, some lung cancers, and other malignancies, this form of cellular immunotherapy has been life-changing for patients. Recent evidence suggests engineering natural killer (NK) cells to express CAR may be equally effective as T cells but with increased safety and clinical feasibility.

There is growing interest in the safety and efficacy of applying CAR cellular therapies to deadly and incurable autoimmune diseases. However, finding specific cell targets for diseases such as lupus has been much more difficultuntil now.

In a first-of-its-kind discovery, a team of Cincinnati Children's scientists led by Seth Reighard, PhD, Stephen Waggoner, PhD, and Hermine Brunner, MD, MSc, MBA, has engineered a CAR with the potential to revolutionize care of patients with lupus. When expressed by human NK cells, this CAR enables targeted elimination of T follicular helper (TFH) cells without harming other types of T-cells.

This treatment showed specificity in human cells in lab tests, and improved disease measures in a humanized mouse model of lupustwo key early signs of progress that suggest further research is warranted.

"This is the first method to specifically remove an otherwise intractable population of harmful cells," Waggoner says. "We think targeting them will be safe and clinically beneficial in multiple diseases. Our approach started with lupus because the disease is a leading cause of death in young women for which a cure is presently lacking."

The study appears in the first issue of the new, open access journal Cell Reports Medicine, which also carries a commentary about this new approach from Cecile King, PhD, an immunology expert at the Garvan Institute of Medical Research in Australia.

"Dysregulated TFH cells are associated with the development and severity of several autoimmune diseases and T cell malignancies," King states. "Indeed, the central role of TFH cells in many diseases has made them a major target for therapeutic modulation. The study by Reighard et al. provides exciting proof-of-principle evidence for the use of CAR NK cells in TFH-driven diseases."

How do CAR NK cells work?

The lupus-driving cells that the team wanted to eliminate lack cell-surface targets unique enough to distinguish them from other, desirable cells. To achieve selective targeting, the team realized a cardinal feature of TFH cells that could be exploited by carefully engineering the biochemistry of the CAR molecule.

Specifically, TFH express much greater quantities of a surface receptor, programmed cell death protein 1 (PD-1), than other cells that also express this receptor. Since activation of a CAR expressing NK cell is dependent on the strength of interaction between the CAR and its target receptor, as well as the number of such interactions between an NK cell and a target, the team engineered a CAR with relatively weak binding to PD-1. As a result, only cells like TFH that exhibit high expression of PD-1 trigger activation of the CAR NK and are eliminated as a result, which cells with lower levels of PD-1, including regulatory T cell (Treg) and memory T cells, are spared.

These programmed killer cells show early signs of potential as a therapy for systemic lupus erythematosus (SLE), which affects 20-150 per 100,000 people in the U.S. In fact, lupus ranks in the five causes of death among African American and Hispanic women, aged 15-34.

In addition, aberrant TFH responses play roles in several other autoimmune diseases, including Sjgren syndrome, juvenile dermatomyositis, multiple sclerosis, type 1 diabetes, and rheumatoid arthritis.

Although the potential toxicity of selectively eliminating TFH remains unexplored, the preservation of naive and memory CD4 T cells as well as B cells and other types of immune cells suggests that the state of immunodeficiency induced by these CAR NK cells will be far less severe than other immunotherapeutic strategies applied to autoimmune disease (e.g., rituximab).

Discovery based on years of research

This advance in CAR technology build upon previous work by Waggoner and colleagues in 2015 and 2018 that revealed how NK cells play surprising regulatory roles in infection and autoimmune disease.

The conceptual connections between infections and autoimmune diseases were further strengthened by a discovery led by John Harley, MD, PhD, and colleagues at Cincinnati Children's. In a 2018 study in Nature Genetics, they revealed how the Epstein-Barr virus uses groups of transcription factors to alter human DNA in ways that can increase a person's risk of developing lupus, multiple sclerosis, type 1 diabetes, and other diseases.

What's Next?

More work is needed to determine how much benefit can be gained by disrupting the role of TFH cells in lupus and other conditions. Concerns to address also include how to prevent the killer cells from attacking non-targeted "good" cells, and how to efficiently deliver the therapeutic cells.

Researchers are working to develop "suicide switches" for CAR NK cells that would make them safer for clinical use, Waggoner says. But importantly, NK cells appear to pose lower toxicity risk than CAR T-cell therapies in multiple clinical trials in cancer patients. Given the contributions of T cells to disease pathogenesis in lupus and other autoimmune disease, therapeutic NK cells likely yield additional benefit in these contexts.

Although the present study was performed with a human NK-cell line approved for clinical use by the FDA, the team envisions flexibility in the clinical application of the new CAR to lupus. CAR engineering of patient cells or cells from unrelated donors, including cord blood or induced pluripotent stem cell-derived NK cells, have all demonstrated excellent safety profiles while maintaining desirable efficacy in clinical trials.

"The CAR can be introduced to various effector cells using mRNA transfection, transposons, or viral vectors, Waggoner says. "Freezers full of CAR-expressing induced pluripotent stem cell-derived NK cells would provide an off-the-shelf product that could be rapidly and repeatedly administered to numerous patients in order to quell harmful flares of disease activity and promote sustained disease remission.

"If successes continue, a clinical trial might be possible within the next few years," Waggoner says.

View original content to download multimedia:http://www.prnewswire.com/news-releases/novel-car-nk-cell-technology-could-lead-to-new-treatments-for-lupus-other-incurable-diseases-301057216.html

SOURCE Cincinnati Children's Hospital Medical Center

Read more from the original source:
Novel CAR NK-cell technology could lead to new treatments for lupus, other incurable diseases - Stockhouse